IFNG and myeloid sarcoma: An independent laboratory found that IFNγ/IL-17-co-expressing CD4+ T cells are abundant in post-mortem MS lesions, and that lymphocytes obtained from relapsing MS patients have a propensity to expand into IFNγ/IL-17 co-producers [93].